We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

59 hedge funds and large institutions have $65.5M invested in Ovid Therapeutics in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

7% more funds holding

Funds holding: 55 → 59 (+4)

1.37% more ownership

Funds ownership: 49.18% → 50.54% (+1.4%)

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

12% less capital invested

Capital invested by funds: $74.5M → $65.5M (-$8.99M)

Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
18
Reduced
18
Closed
6
Calls
$52K
Puts
–
Net Calls
+$52K
Net Calls Change
-$64K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$3.42M
2
MAP
Madison Avenue Partners
New York
+$2.92M
3
OMC
Oasis Management Company
Cayman Islands
+$421K
4
DCM
Driehaus Capital Management
Illinois
+$182K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$95.2K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$4.07M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$414K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$255K
4
First Trust Advisors
First Trust Advisors
Illinois
-$174K
5
BCM
Bridgeway Capital Management
Texas
-$157K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$12.6M – – –
EC
2
EcoR1 Capital
California
$11.3M – – –
RCMNY
3
Rubric Capital Management (New York)
New York
$8.31M +$3.42M +1,633,594 +57%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.75M +$95.2K +45,500 +2%
AG
5
Artal Group
Luxembourg
$4.6M – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$3.36M -$255K -122,111 -6%
SCM
7
Stonepine Capital Management
Oregon
$2.83M -$4.07M -1,947,257 -56%
DCM
8
Driehaus Capital Management
Illinois
$2.63M +$182K +86,943 +6%
MAP
9
Madison Avenue Partners
New York
$2.56M +$2.92M +1,394,022 New
BlackRock
10
BlackRock
New York
$2.13M -$36.5K -17,466 -1%
BCM
11
Bridgeway Capital Management
Texas
$1.67M -$157K -75,200 -8%
CA
12
CHI Advisors
New York
$1.59M – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$1.27M -$414K -198,041 -22%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$905K +$7.61K +3,637 +0.7%
Wells Fargo
15
Wells Fargo
California
$800K +$5.9K +2,819 +0.7%
OMC
16
Oasis Management Company
Cayman Islands
$497K +$421K +201,200 +292%
Russell Investments Group
17
Russell Investments Group
United Kingdom
$492K +$1.77K +847 +0.3%
Millennium Management
18
Millennium Management
New York
$424K -$29.4K -14,046 -6%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$411K +$9.63K +4,601 +2%
State Street
20
State Street
Massachusetts
$353K – – –
DA
21
DCF Advisers
Connecticut
$299K +$43.9K +21,000 +15%
Renaissance Technologies
22
Renaissance Technologies
New York
$219K -$10.5K -5,000 -4%
Northern Trust
23
Northern Trust
Illinois
$179K +$29.5K +14,121 +17%
Fidelity Investments
24
Fidelity Investments
Massachusetts
$170K -$4.18K -2,000 -2%
Boston Partners
25
Boston Partners
Massachusetts
$142K +$1.77K +847 +1%
1
2 3

OVID Hedge Fund Activity: Q3 2022 in Review

59 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2022, worth a combined $65.5M — down 12% from $74.5M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new OVID positions and 6 closed out — a net gain of 4 holders — while 18 added to existing stakes and 18 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $3.42M. The largest seller was Stonepine Capital Management, cutting an estimated $4.07M.

  • 59 institutional investors held Ovid Therapeutics (OVID) as of Q3 2022, up from 55 in Q2 2022.
  • Funds reported $65.5M of Ovid Therapeutics stock for Q3 2022, down 12% quarter-over-quarter.
  • 10 funds opened new Ovid Therapeutics positions in Q3 2022 and 6 closed out, a net change of +4 holders.
  • The largest Ovid Therapeutics buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $3.42M added.
  • The largest Ovid Therapeutics seller in Q3 2022 was Stonepine Capital Management, an estimated $4.07M sold.

Based on aggregated 13F filings for Q3 2022.